Literature DB >> 21102440

MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling.

Paula A da Costa Martins1, Kanita Salic, Monika M Gladka, Anne-Sophie Armand, Stefanos Leptidis, Hamid el Azzouzi, Arne Hansen, Christina J Coenen-de Roo, Marti F Bierhuizen, Roel van der Nagel, Joyce van Kuik, Roel de Weger, Alain de Bruin, Gianluigi Condorelli, Maria L Arbones, Thomas Eschenhagen, Leon J De Windt.   

Abstract

MicroRNAs (miRs) are a class of single-stranded, non-coding RNAs of about 22 nucleotides in length. Increasing evidence implicates miRs in myocardial disease processes. Here we show that miR-199b is a direct calcineurin/NFAT target gene that increases in expression in mouse and human heart failure, and targets the nuclear NFAT kinase dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1a (Dyrk1a), constituting a pathogenic feed forward mechanism that affects calcineurin-responsive gene expression. Mutant mice overexpressing miR-199b, or haploinsufficient for Dyrk1a, are sensitized to calcineurin/NFAT signalling or pressure overload and show stress-induced cardiomegaly through reduced Dyrk1a expression. In vivo inhibition of miR-199b by a specific antagomir normalized Dyrk1a expression, reduced nuclear NFAT activity and caused marked inhibition and even reversal of hypertrophy and fibrosis in mouse models of heart failure. Our results reveal that microRNAs affect cardiac cellular signalling and gene expression, and implicate miR-199b as a therapeutic target in heart failure.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21102440     DOI: 10.1038/ncb2126

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  33 in total

Review 1.  Sizing up the heart: development redux in disease.

Authors:  Eric N Olson; Michael D Schneider
Journal:  Genes Dev       Date:  2003-07-31       Impact factor: 11.361

2.  A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT.

Authors:  Yousang Gwack; Sonia Sharma; Julie Nardone; Bogdan Tanasa; Alina Iuga; Sonal Srikanth; Heidi Okamura; Diana Bolton; Stefan Feske; Patrick G Hogan; Anjana Rao
Journal:  Nature       Date:  2006-03-01       Impact factor: 49.962

3.  microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart.

Authors:  Ning Liu; Svetlana Bezprozvannaya; Andrew H Williams; Xiaoxia Qi; James A Richardson; Rhonda Bassel-Duby; Eric N Olson
Journal:  Genes Dev       Date:  2008-11-17       Impact factor: 11.361

Review 4.  Transcriptional regulation by calcium, calcineurin, and NFAT.

Authors:  Patrick G Hogan; Lin Chen; Julie Nardone; Anjana Rao
Journal:  Genes Dev       Date:  2003-09-15       Impact factor: 11.361

5.  Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo.

Authors:  B A Rothermel; T A McKinsey; R B Vega; R L Nicol; P Mammen; J Yang; C L Antos; J M Shelton; R Bassel-Duby; E N Olson; R S Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

6.  Conditional expression of SV40 T-antigen in mouse cardiomyocytes facilitates an inducible switch from proliferation to differentiation.

Authors:  Igor I Rybkin; David W Markham; Zhen Yan; Rhonda Bassel-Duby; R Sanders Williams; Eric N Olson
Journal:  J Biol Chem       Date:  2003-02-17       Impact factor: 5.157

7.  NFATc2 is a necessary mediator of calcineurin-dependent cardiac hypertrophy and heart failure.

Authors:  Meriem Bourajjaj; Anne-Sophie Armand; Paula A da Costa Martins; Bart Weijts; Roel van der Nagel; Sylvia Heeneman; Xander H Wehrens; Leon J De Windt
Journal:  J Biol Chem       Date:  2008-05-12       Impact factor: 5.157

8.  MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts.

Authors:  Scot J Matkovich; Wei Wang; Yizheng Tu; William H Eschenbacher; Lisa E Dorn; Gianluigi Condorelli; Abhinav Diwan; Jeanne M Nerbonne; Gerald W Dorn
Journal:  Circ Res       Date:  2009-11-05       Impact factor: 17.367

9.  MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice.

Authors:  Angelika Bonauer; Guillaume Carmona; Masayoshi Iwasaki; Marina Mione; Masamichi Koyanagi; Ariane Fischer; Jana Burchfield; Henrik Fox; Carmen Doebele; Kisho Ohtani; Emmanouil Chavakis; Michael Potente; Marc Tjwa; Carmen Urbich; Andreas M Zeiher; Stefanie Dimmeler
Journal:  Science       Date:  2009-05-21       Impact factor: 47.728

10.  Specificity, duplex degradation and subcellular localization of antagomirs.

Authors:  Jan Krützfeldt; Satoru Kuwajima; Ravi Braich; Kallanthottathil G Rajeev; John Pena; Thomas Tuschl; Muthiah Manoharan; Markus Stoffel
Journal:  Nucleic Acids Res       Date:  2007-04-16       Impact factor: 16.971

View more
  125 in total

1.  O-GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy.

Authors:  Heberty T Facundo; Robert E Brainard; Lewis J Watson; Gladys A Ngoh; Tariq Hamid; Sumanth D Prabhu; Steven P Jones
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-09       Impact factor: 4.733

Review 2.  Antisense MicroRNA Therapeutics in Cardiovascular Disease: Quo Vadis?

Authors:  Leonne E Philippen; Ellen Dirkx; Jan B M Wit; Koos Burggraaf; Leon J de Windt; Paula A da Costa Martins
Journal:  Mol Ther       Date:  2015-07-28       Impact factor: 11.454

3.  Molecular Pathogenesis of Chlamydia Disease Complications: Epithelial-Mesenchymal Transition and Fibrosis.

Authors:  Joseph U Igietseme; Yusuf Omosun; Tamas Nagy; Olga Stuchlik; Matthew S Reed; Qing He; James Partin; Kahaliah Joseph; Debra Ellerson; Zenas George; Jason Goldstein; Francis O Eko; Claudiu Bandea; Jan Pohl; Carolyn M Black
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

4.  p53 downregulates Down syndrome-associated DYRK1A through miR-1246.

Authors:  Yu Zhang; Jun-Ming Liao; Shelya X Zeng; Hua Lu
Journal:  EMBO Rep       Date:  2011-06-03       Impact factor: 8.807

Review 5.  Therapeutic use of microRNAs in myocardial diseases.

Authors:  Michael V G Latronico; Gianlugi Condorelli
Journal:  Curr Heart Fail Rep       Date:  2011-09

Review 6.  MicroRNAs in cardiovascular ageing.

Authors:  Timon Seeger; Reinier A Boon
Journal:  J Physiol       Date:  2015-07-05       Impact factor: 5.182

7.  Analysis of the microRNA signature driving adaptive right ventricular hypertrophy in an ovine model of congenital heart disease.

Authors:  Rebecca Johnson Kameny; Youping He; Terry Zhu; Wenhui Gong; Gary W Raff; Cheryl J Chapin; Sanjeev A Datar; Jason T Boehme; Akiko Hata; Jeffrey R Fineman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-06-15       Impact factor: 4.733

Review 8.  MicroRNAs in stress signaling and human disease.

Authors:  Joshua T Mendell; Eric N Olson
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

9.  MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca²⁺ overload and cell death.

Authors:  Arin B Aurora; Ahmed I Mahmoud; Xiang Luo; Brett A Johnson; Eva van Rooij; Satoshi Matsuzaki; Kenneth M Humphries; Joseph A Hill; Rhonda Bassel-Duby; Hesham A Sadek; Eric N Olson
Journal:  J Clin Invest       Date:  2012-03-19       Impact factor: 14.808

10.  A cardiac-enriched microRNA, miR-378, blocks cardiac hypertrophy by targeting Ras signaling.

Authors:  Raghu S Nagalingam; Nagalingam R Sundaresan; Mahesh P Gupta; David L Geenen; R John Solaro; Madhu Gupta
Journal:  J Biol Chem       Date:  2013-02-27       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.